-
-
#plausible. do you know if those are published data? -
They are well known, especially for TNBC. The pCR rate for HER2(+)/HR(-) disease is according to more recent publications. It's due to the addition of the new HER2-targeted monoclonal antibody Perjeta.
- Show replies
New conversation -
-
-
Unfortunately, the most common breast cancer subtype, HR(+)/HER2(-), is a lot less chemosensitive, with a pCR rate after neoadjuvant chemotherapy of well under 10%.
-
yes--that's the main experience, AYK, and why it's often futile giving traditional chemo for advanced BC
End of conversation
New conversation -
-
-
That makes more sense - omitting surgery after NAC if radiological response.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.